Ractigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5016662_CN16662_0